These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 27559940

  • 1. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW, Yang SF, Yeh YP, Tsao TC, Tsao SM.
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR.
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [Abstract] [Full Text] [Related]

  • 4. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, Ruan SY, Wang JY, Wang JT.
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [Abstract] [Full Text] [Related]

  • 5. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT, McBryde ES, Eisen D, Street A, Matchett E, Chen C, Shultz TR, Biggs B, Leder K.
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
    Holland DP, Sanders GD, Hamilton CD, Stout JE.
    Am J Respir Crit Care Med; 2009 Jun 01; 179(11):1055-60. PubMed ID: 19299495
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM.
    Ann Pharmacother; 2020 May 01; 54(5):457-463. PubMed ID: 31729245
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G, Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T, Bamrah-Morris S, Ho CS.
    Clin Infect Dis; 2017 Oct 01; 65(7):1085-1093. PubMed ID: 28575208
    [Abstract] [Full Text] [Related]

  • 14. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL, Lee MR, Lee CH, Cheng MH, Lu PL, Sheu CC, Wang JY, Chong IW, Yang JM.
    Clin Microbiol Infect; 2024 Nov 01; 30(11):1410-1417. PubMed ID: 38996972
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT, Churchyard GJ, Sohn H, Dowdy DW.
    Clin Infect Dis; 2018 Sep 14; 67(7):1072-1078. PubMed ID: 29617965
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
    Pease C, Alvarez G, Mallick R, Patterson M, Finn S, Habis Y, Schwartzman K, Kilabuk E, Mulpuru S, Zwerling A.
    BMJ Open; 2021 May 13; 11(5):e047514. PubMed ID: 33986067
    [Abstract] [Full Text] [Related]

  • 18. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME, TB Trials Consortium.
    Int J Tuberc Lung Dis; 2015 Sep 13; 19(9):1039-44, i-v. PubMed ID: 26260821
    [Abstract] [Full Text] [Related]

  • 19. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS, TB Trials Consortium iAdhere Study Team.
    Ann Intern Med; 2017 Nov 21; 167(10):689-697. PubMed ID: 29114781
    [Abstract] [Full Text] [Related]

  • 20. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY, Chiu YW, Lu PL, Hwang SJ, Chen TC, Hsieh MH, Chen YH.
    J Microbiol Immunol Infect; 2019 Feb 21; 52(1):158-162. PubMed ID: 29907535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.